AGP Executive Report
Last update: 3 hours agoHealth Coverage: New Jersey residents can begin choosing 2027 ACA plans Nov. 1, as health costs rise. State officials also warn proposed Medicaid cuts could cost New Jersey $3.7 billion a year and leave thousands uninsured. Cancer Research: Rahway-based Merck says its investigational drug sac-TMT cut the risk of death by 32% and disease progression or death by 41% versus chemotherapy in a Phase 3 trial involving some patients with advanced or recurrent endometrial cancer. Food Safety: The FDA classified a recall of Miyoko’s Creamery salted plant butter over yeast, mold and possible E. coli contamination. The product was distributed in New Jersey; no illnesses have been reported. Local Health: A Rutgers senior is mapping sewer overflows along the Lower Passaic River, focusing attention on pollution in the region. Drug Ads: A federal judge in Trenton declined to block Eli Lilly’s weight-loss drug ads while Novo Nordisk’s false-advertising lawsuit continues.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
